Probiotic Clostridium butyricum ameliorated motor deficits in a mouse model of Parkinson's disease via gut microbiota-GLP-1 pathway

Brain Behav Immun. 2021 Jan:91:703-715. doi: 10.1016/j.bbi.2020.10.014. Epub 2020 Oct 24.

Abstract

A connection between gut microbiota and Parkinson's disease (PD) indicates that dysbiosis of the gut microbiota might represent a risk factor for PD. Microbiota-targeted interventions, including probiotic Clostridium butyricum (Cb), have been recently shown to have favorable effects in PD by regulating microbiota-gut-brain axis. However, the potential beneficial roles and its mechanisms of Cb on PD were still unknown. Male C57BL/6 mice were subjected to a PD model-induced by 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine (MPTP) and were treated intragastrically with Cb for 4 weeks. The motor functions were assessed by a series of behavioral tests including pole test, beam walking teat, forced swimming test and open field test. The dopaminergic neuron loss, synaptic plasticity and microglia activation, as well as the levels of colonic glucagon-like peptide-1 (GLP-1), colonic G protein-coupled receptors GPR41/43 and cerebral GLP-1 receptors were assessed. Gut microbial composition was assessed by 16S rRNA sequencing analysis. Our results showed that oral administration of Cb could improve motor deficits, dopaminergic neuron loss, synaptic dysfunction and microglia activation in the MPTP-induced mice. Meanwhile, Cb treatment could reverse the dysbiosis of gut microbiota and the decreased levels of colonic GLP-1, colonic GPR41/43 and cerebral GLP-1 receptor in the MPTP-induced mice. These findings indicated that the neuroprotective mechanism of Cb on PD might be related to the improvement of abnormal gut microbiota-gut-brain axis.

Keywords: Clostridium butyricum; Glucagon-like peptide-1; Gut microbiota; Gut-brain axis; Neuroprotection; Parkinson’s disease.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Clostridium butyricum*
  • Disease Models, Animal
  • Dopaminergic Neurons
  • Gastrointestinal Microbiome*
  • Glucagon-Like Peptide 1
  • Male
  • Mice
  • Mice, Inbred C57BL
  • Neuroprotective Agents*
  • Parkinson Disease*
  • Probiotics*
  • RNA, Ribosomal, 16S

Substances

  • Neuroprotective Agents
  • RNA, Ribosomal, 16S
  • Glucagon-Like Peptide 1